EUCTR2010-020386-24-NL进行中（未招募）不适用
Phase II, multicenter, randomized, adaptive, double-blind, placebo controlled study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patients.
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- TROPHOS SA
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Weakness and hypotonia consistent with a clinical diagnosis of spinal muscular atrophy(SMA) type II or III
- •2. Laboratory documentation of homozygous absence of SMNI exon 7 and/or deletion
- •and mutation on other allele
- •3. MFM score =15% (D1 + D2 score)
- •4. HFMS score at baseline = 3
- •5. Non ambulant patients defined as patients with HFMS score = 38
- •6. Must be 3 years of age or older, but younger than 26 years of age, at time of enrolment
- •7. Age of onset of symptoms = 3 years of age
- •8. Signed informed consent of patient and/or parents/guardian
- •9. Laboratory results drawn within 31 days prior to start of study entry demonstrating no clinically significant abnormalities
- •10. Ability to take the study treatment (tested at screening after informed consent)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects who meet one or more of the following criteria are not allowed to be included in the study:
- •1. Evidence of renal dysfunction, blood dysplasia, hepatic insufficiency, symptomatic
- •pancreatitis, cardiac arrhythmia, congenital heart defect, known history of metabolic
- •acidosis, hypertension, significant central nervous system impairment, or neurodegenerative or neuromuscular disease other than SMA
- •2. Any clinically significant ECG abnormality
- •3. Any acute co-morbid condition interfering with the well-being of the subject within 7 days of enrolment including bacterial infection, viral infectious processes, food poisoning, temperature > 37.0 °C, the need for acute treatment or observation due to any other reason, as judged by the investigator; patient can be included after resolution of the acute event
- •4. Use of medications intended for the treatment of SMA including riluzole, valproic
- •acid, hydroxyurea, sodium phenylbutyrate, butyrate derivatives, creatine, carnitine,
- •growth hormone, anabolic steroids, probenecid, oral or parenteral use of corticosteroids at entry, agents anticipated to increase or decrease muscle strength or agents with known or presumed histone deacetylase (HDAC) inhibition, within 30 days prior to study entry. Subjects who use a nebulizer or require an inhaler to steroids will be allowed in the study; however oral use of steroids is prohibited.
- •The oral use of salbutamol is permitted with the following restrictions: patients should have been on salbutamol for at least 6 months before inclusion in the trial, with good tolerance. The dose of salbutamol should remain constant for the duration of the trial.
- •5. Spinal rod or fixation for scoliosis within the past 6 months or anticipated need of rod or fixation within 6 months of enrolment.
- •6. Inability to meet study visit requirements or cooperate reliably with functional testing
- •7. Coexisting medical conditions that contraindicate travel, testing or study medications
- •8. Current or planned pregnancy or nursing period
- •9. For Women: Failure to use one of the following safe methods of contraception:
- •a) Female condoms, diaphragm or coil, each used in combination with spermicides
- •b) Intra-uterine device
- •c) Hormonal contraception in combination with a mechanical method of contraception
- •10. Participation in any other investigational drug or therapy study within the previous 3 months.
研究者
相似试验
进行中（未招募）
1 期
Phase II, multicenter, randomized, adaptive, double-blind, placebo controlled study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patients.EUCTR2010-020386-24-DETROPHOS SA150
进行中（未招募）
1 期
Safety and Efficacy of Olesoxime (TRO19622) in 3-25 yrs SMA patientsEUCTR2010-020386-24-GBTROPHOS SA165
进行中（未招募）
1 期
Phase II, multicenter, randomized, adaptive, double-blind, placebo controlled study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patients.Spinal Muscular Atrophy (type 2 or type 3 non ambulant patients aged 3-25 years)MedDRA version: 12.1Level: LLTClassification code 10041582Term: Spinal muscular atrophyEUCTR2010-020386-24-FRTROPHOS SA
已完成
2 期
Phase II, multicenter, randomized, adaptive, double-blind,placebo controlled Study to assess Safety and Efficacy of olesoxime(TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patientsMedDRA - 12.1 LLT 10041582 Spinal Muscular AtrophyG12Spinal muscular atrophy and related syndromesDRKS00000814TROPHOS SA165
进行中（未招募）
1 期
Phase II, multicenter, randomized, adaptive, double-blind, placebo controlled study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patients.EUCTR2010-020386-24-BETROPHOS SA150